BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
Globe Newswire•18/08/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.